Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01869777 · ClinicalTrials.gov registry record · NA
Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia
A NA study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 102
- Enrollment target
NCT01869777 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 102 participants.
The verdict
NCT01869777, a NA study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 102 participants
- Enrollment target
Study Summary
This clinical trial studies bioelectrical impedance measurement for predicting treatment outcome in patients with newly diagnosed acute leukemia. Diagnostic procedures, such as bioelectrical impedance measurement, may help predict a patient's response to treatment for acute leukemia.
Interventions
- PROCEDURE bioelectric impedance analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2013-07 |
| Est. Completion | 2020-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01869777
The ClinicalTrials.gov registry entry for NCT01869777 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bioelectric impedance analysis is the first listed.
NCT01869777 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01869777 about?
NCT01869777 is a clinical study titled "Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia". This clinical trial studies bioelectrical impedance measurement for predicting treatment outcome in patients with newly diagnosed acute leukemia. Diagnostic procedures, such as bioelectrical impedance measurement, may help predict a patient's response to treatment for acute leukemia.
What is the current status of trial NCT01869777?
This trial is currently completed. It is a NA study. The enrollment target is 102 participants. The study started on 2013-07. Estimated completion is 2020-05.
What interventions are being tested in trial NCT01869777?
The interventions under investigation include: bioelectric impedance analysis (PROCEDURE).
Who is sponsoring clinical trial NCT01869777?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.